MarketPulse

PDUFA date

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Aquestive Stock Crashes 37% After FDA Rejection; Class Action Deadline Set for May 4

Class action lawsuit filed against Aquestive Therapeutics after company failed to disclose FDA deficiencies blocking Anaphylm approval, triggering 37% stock decline.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Aquestive Faces Class Action Over Anaphylm Drug Approval Misstatements

Portnoy Law Firm files class action against Aquestive Therapeutics for allegedly misleading investors about Anaphylm drug approval prospects, citing undisclosed FDA deficiencies.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Faces Class Action Over Anaphylm FDA Approval Claims

Class action lawsuit filed against $AQST alleging securities fraud over false FDA timeline statements and concealed safety risks for Anaphylm drug.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Faces Securities Fraud Lawsuit Over FDA Approval Claims

Class action lawsuit filed against $AQST alleging executives made false statements about Anaphylm FDA approval timeline and concealed human factors risks.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Aquestive Faces Class Action Over Anaphylm FDA Approval Misstatements

Aquestive Therapeutics faces class action lawsuit alleging FDA approval misrepresentations for Anaphylm. Stock dropped 37% January 9; lead plaintiff applications due May 4, 2026.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Hit With Securities Fraud Suit Over Anaphylm FDA Timeline Claims

Class action lawsuit filed against Aquestive Therapeutics alleging securities fraud related to Anaphylm FDA approval timeline and undisclosed human factors risks.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Faces Securities Fraud Suit Over FDA Approval Claims

Class action lawsuit filed against $AQST alleging misleading statements about FDA approval timeline for Anaphylm and concealed human factors risks.
AQSTsecurities fraudclass action lawsuit